TrialDiabetes, obesity & metabolism2014

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

S Macha et al.PubMed ↗Publisher ↗

No numbers read from the abstract.